Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Neuroendocrine × Standard of Care × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 8 Neoplasm Metastasis 7 Carcinoma, Non-Small-Cell Lung 7 Neoplasms 6 Urinary Bladder Neoplasms 5 Leukemia, Myeloid, Acute 5 Colorectal Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Prostatic Neoplasms 4 Lung Neoplasms 4 Triple Negative Breast Neoplasms 3 Ovarian Neoplasms 3 Mouth Neoplasms 3 Head and Neck Neoplasms 3 Carcinoma, Transitional Cell 3 Carcinoma, Ovarian Epithelial 3 Ureteral Neoplasms 2 Recurrence 2 Oropharyngeal Neoplasms 2 Melanoma 2 Laryngeal Neoplasms 2 Glioblastoma 2 Gastrointestinal Neoplasms 2 Carcinoma 2 COVID-19 2 Brain Neoplasms 2 Adenocarcinoma 2 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Tonsillar Neoplasms 1

Interventions

Everolimus 9 Cisplatin 7 Temozolomide 5 Bevacizumab 5 lutetium Lu 177 dotatate 4 Nivolumab 4 Etoposide 4 Carboplatin 4 Capecitabine 4 Irinotecan 3 sintilimab 2 pembrolizumab 2 dostarlimab 2 cabozantinib 2 azaspirane 2 avelumab 2 atezolizumab 2 Paclitaxel 2 Ipilimumab 2 Immunoglobulin G 2 IFL protocol 2 Fluorouracil 2 Fluorodeoxyglucose F18 2 Disulfides 2 zimberelimab 1 surufatinib 1 selinexor 1 pertuzumab 1 pasireotide 1 niraparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07337447 2026-01-13

REWENEC 01

Hospices Civils de Lyon

Phase 2 Not yet recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡